REG - Silence Therapeutics - Update on AIM Delisting

Silence TherapeuticsAnnouncement

26/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211126:nRSZ6292Ta&default-theme=true

RNS Number : 6292T  Silence Therapeutics PLC  26 November 2021

 

 

Silence Therapeutics plc: Update on AIM Delisting

 

26 November 2021

 

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN ("Silence" or "the
Company"), a leader in the discovery, development and delivery of novel short
interfering ribonucleic acid (siRNA) therapeutics for the treatment of
diseases with significant unmet medical need, today provides a further update
with respect to the cancellation of admission of its ordinary shares of
nominal value £0.05 each (the "Ordinary Shares") to trading on AIM (the "AIM
Delisting"), as originally announced on 15 October 2021.

 

As previously announced, the last day of trading of the Company's Ordinary
Shares on AIM will be 29 November 2021 and the proposed AIM Delisting will be
effective from 7.00 a.m. (London time) on 30 November 2021. Silence will
retain the listing of its American Depositary Shares, each representing three
Ordinary Shares (the "ADSs"), on the Nasdaq Global Market ("Nasdaq") under the
ticker symbol SLN. Following the AIM Delisting, the Company's ADSs will remain
listed, and will only be tradeable, on Nasdaq.

 

Information about the process to deposit Ordinary Shares for delivery of ADSs
was provided in the announcement and circular published by the Company on 15
October 2021 and is also available on the Company's website at
www.silence-therapeutics.com/investors/AIM-Delisting.

 

Following the AIM Delisting, Investec Bank plc will cease to act as nominated
adviser and broker to the Company.

 

Enquiries:

 

 Silence Therapeutics plc                                   Tel:  +1 (646) 637-3208

  Gem Hopkins, Head of IR & Corporate Communications

 Investec Bank plc (Nominated Adviser and Broker)           Tel:  +44 (0) 20 7597 5970

 Daniel Adams/Gary Clarence

 European PR                                                Tel: +44 (0) 20 3709 5700

 Consilium Strategic Communications

 Mary-Jane Elliott/Angela Gray/Chris Welsh

 silencetherapeutics@consilium-comms.com

 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing
the body's natural mechanism of RNA interference, or RNAi, to inhibit the
expression of specific target genes thought to play a role in the pathology of
diseases with significant unmet medical need. Silence's proprietary mRNAi
GOLD™ platform can be used to create siRNAs that precisely target and
silence disease-associated genes in the liver, which represents a substantial
opportunity. Silence's wholly owned product candidates include SLN360 designed
to address the high and prevalent unmet medical need in reducing
cardiovascular risk in people born with high levels of lipoprotein(a) and
SLN124 designed to address iron loading anemias. Silence also maintains
ongoing research and development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Hansoh Pharma, among others. For more information, please
visit https://www.silence-therapeutics.com/.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFEEFDIEFSESF